8-K current report · filed Nov 20, 2026

Compass Therapeutics, Inc. (CMPX) 8-K Current Report: November 20, 2026

Item 3.01CMPX overview

Short answer

Compass Therapeutics, Inc. (CMPX) filed an 8-K current report with the SEC on November 20, 2026 reporting Item 3.01 (Notice of Delisting). Nasdaq deficiency: CMPX closing bid below $1.00 for 30 consecutive business days.

  • This filing includes Item 3.01, an item that often signal trouble.

Why these 8-K items matter →

Compass Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 3.01 · Notice of Delisting

  • Nasdaq deficiency: CMPX closing bid below $1.00 for 30 consecutive business days
  • Immediate delisting not triggered: shares continue trading on Nasdaq Capital Market
  • Compliance deadline May 18, 2027, requiring at least $1.00 bid for 10 consecutive business days
  • Potential second 180-day cure period, contingent on meeting other Nasdaq listing standards
  • Reverse stock split remains a possible remedy, creating dilution and trading-volatility risk for shareholders

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Compass Therapeutics, Inc. 8-K filings

Get the next CMPX 8-K as it lands

Follow CMPX for push alerts, or ask the research agent what this filing means.